Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2

✍ Scribed by Shu-Chen Chu; Hui-Ling Chiou; Pei-Ni Chen; Shun-Fa Yang; Yih-Shou Hsieh

• Publisher: John Wiley and Sons
• Year: 2004
• Tongue: English
• Weight: 197 KB
• Volume: 40
• Category: Article
• ISSN: 0899-1987
• DOI: 10.1002/mc.20018

✦ Synopsis

Abstract

Cancer metastasis, involving multiple processes and various cytophysiological changes, is a primary cause of cancer death and may complicate the clinical management, even lead to death. Silibinin is a flavonoid antioxidant and wildly used for its antihepatotoxic properties and recent studies have revealed pleiotropic anticancer and antiproliferative capabilities of silibinin. In this study, we first observed that silibinin exerted a dose‐ and time‐dependent inhibitory effect on the invasion and motility, but hardly on the adhesion, of highly metastatic A549 cells in the absence of cytotoxicity. To look at the precise involvement of silibinin in cancer metastasis, A549 cells were treated with silibinin at various concentrations, up to 100 μM, for a defined period and then subjected to gelatin zymography, casein zymography and Western blot to investigate the impacts of silibinin on metalloproteinase‐2 (MMP‐2), urokinase plasminogen activator (u‐PA), and tissue inhibitor of metalloproteinase‐2 (TIMP‐2), respectively. The results showed that a silibinin treatment may decrease the expressions of MMP‐2 and u‐PA in a concentration‐ and time‐dependent manner and enhance the expression of TIMP‐2. Further analysis with semi‐quantitative RT‐PCR showed that silibinin may regulate the expressions of MMP‐2 and u‐PA on the transcriptional level while on the translational or post‐translational level for TIMP‐2. © 2004 Wiley‐Liss, Inc.